CD19 and cancer: In this large-scale trial, 11 patients with R/R CD19-positive cancers (non-Hodgkin’s lymphoma or chronic lymphocytic leukemia) received an allogeneic CB-derived CAR-NK cell product after lymphodepleting chemotherapy [173].